Firefly Neuroscience (NASDAQ:AIFF) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Firefly Neuroscience (NASDAQ:AIFF) from a sell rating to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings lowered Firefly Neuroscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Firefly Neuroscience Stock Performance

Firefly Neuroscience stock opened at $1.70 on Friday. The stock has a 50-day moving average of $1.96 and a two-hundred day moving average of $1.48. Firefly Neuroscience has a one year low of $0.62 and a one year high of $3.77. The stock has a market cap of $26.47 million, a PE ratio of -2.70 and a beta of 0.60.

Firefly Neuroscience (NASDAQ:AIFF) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter. The business had revenue of $0.49 million during the quarter. Firefly Neuroscience had a negative net margin of 565.40% and a negative return on equity of 94.68%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AIFF. Geode Capital Management LLC increased its holdings in shares of Firefly Neuroscience by 92.9% in the second quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after purchasing an additional 58,067 shares during the period. Savvy Advisors Inc. acquired a new position in shares of Firefly Neuroscience in the third quarter valued at about $63,000. Vanguard Group Inc. grew its holdings in Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after acquiring an additional 401,085 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Firefly Neuroscience during the fourth quarter worth about $53,000. 4.96% of the stock is owned by institutional investors and hedge funds.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.